Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A2 | O43868 | 18/20 | 1.00 |
| ▸ | HSPA8 | P11142 | 5/20 | 1.00 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765512 | 1.00 | SLC28A2 (1.00) | SLC28A2HSPA8HSPA5 | |
| SCHEMBL13127254 | 0.96 | SLC28A2 (0.93) | SLC28A2HSPA8HSPA5 | |
| SCHEMBL13127272 | 0.94 | SLC28A2 (1.00) | SLC28A2HSPA8 | |
| SCHEMBL2574129 | 0.94 | SLC28A2 (1.00) | SLC28A2HSPA8 | |
| SCHEMBL31387916 | 0.94 | SLC28A2 (1.00) | SLC28A2HSPA8 | |
| SCHEMBL13127253 | 0.92 | SLC28A2 (0.85) | SLC28A2HSPA8HSPA5 | |
| SCHEMBL13127251 | 0.92 | SLC28A2 (0.85) | SLC28A2HSPA8HSPA5 | |
| SCHEMBL13127255 | 0.92 | SLC28A2 (0.85) | SLC28A2HSPA8HSPA5 | |
| SCHEMBL6758929 | 0.91 | HSPA8 (1.00) | SLC28A2HSPA8HSPA5 | |
| SCHEMBL2568779 | 0.91 | SLC28A2 (0.83) | SLC28A2HSPA8HSPA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | claimed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | claimed |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | DEVOS RENE (GB) | 2004-06-10 | — | — | US | disclosed |
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | F. HOFFMAN-LA ROCHE, A SWISS COMPANY (CH) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008841-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | SLC28A2 34/4885HSPA8 1847/4885HSPA5 1928/4885 |
| US-20040110718-A1 | Anti-HCV nucleoside derivatives | PNP, HAVCR2, NUDT14 | SLC28A2 34/4885HSPA8 1847/4885HSPA5 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.